Sanofi Financials
| SNYN Stock | MXN 991.38 27.38 2.84% |
Sanofi |
Please note, the imprecision that can be found in Sanofi's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sanofi. Check Sanofi's Beneish M Score to see the likelihood of Sanofi's management manipulating its earnings.
Sanofi Stock Summary
Sanofi competes with Eli Lilly, Roche Holding, Gilead Sciences, and Biogen. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. SANOFI is traded on Mexico Stock Exchange in Mexico.| Instrument | Mexico Stock View All |
| Exchange | Mexican Exchange |
| ISIN | US80105N1054 |
| Business Address | 54, Rue La |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.sanofi.com |
| Phone | 33 1 53 77 40 00 |
| Currency | MXN - Mexican Peso |
You should never invest in Sanofi without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sanofi Stock, because this is throwing your money away. Analyzing the key information contained in Sanofi's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sanofi Key Financial Ratios
Sanofi's financial ratios allow both analysts and investors to convert raw data from Sanofi's financial statements into concise, actionable information that can be used to evaluate the performance of Sanofi over time and compare it to other companies across industries.| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Number Of Employees | 58 | |||
| Beta | 0.41 | |||
| Z Score | 89.4 |
Sanofi Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sanofi's current stock value. Our valuation model uses many indicators to compare Sanofi value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sanofi competition to find correlations between indicators driving Sanofi's intrinsic value. More Info.Sanofi is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sanofi is roughly 1.58 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sanofi by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sanofi's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sanofi Systematic Risk
Sanofi's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sanofi volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Sanofi correlated with the market. If Beta is less than 0 Sanofi generally moves in the opposite direction as compared to the market. If Sanofi Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sanofi is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sanofi is generally in the same direction as the market. If Beta > 1 Sanofi moves generally in the same direction as, but more than the movement of the benchmark.
Sanofi December 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sanofi help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sanofi. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sanofi based on widely used predictive technical indicators. In general, we focus on analyzing Sanofi Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sanofi's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 10.25 | |||
| Value At Risk | (2.89) | |||
| Potential Upside | 1.17 |
Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.